Reversal of established autoimmune diabetes by restoration of endogenous beta cell function
about
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetesReversal of Sjogren's-like syndrome in non-obese diabetic miceAll beta cells contribute equally to islet growth and maintenance.Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice.Regeneration of the pancreatic beta cell.Slow and steady is the key to beta-cell replication.Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia.The effect of a novel curcumin derivative on pancreatic islet regeneration in experimental type-1 diabetes in rats (long term study).Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjögren's-like diseaseInosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes.Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models.CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.Reversal of established autoimmune diabetes by in situ beta-cell regeneration.Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.Human pancreatic islet-derived progenitor cell engraftment in immunocompetent mice.Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes.Tolerance induction and endogenous regeneration of pancreatic beta-cells in established autoimmune diabetes.Treatment with incomplete Freund's adjuvant and Listeria monocytogenes delays diabetes via an interleukin-17-secretion-independent pathwayComparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton's Jelly, Bone Marrow, and Pancreatic Tissues.Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic ratsImmunomodulatory therapy of human type 1 diabetes: lessons from the mouseDifferentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model.The Spleen Is an Ideal Site for Inducing Transplanted Islet Graft Expansion in Mice.Development of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetes.Bone marrow cells are a source of undifferentiated cells to prevent Sjögren's syndrome and to preserve salivary glands function in the non-obese diabetic miceLiver-spleen axis: intersection between immunity, infections and metabolismCellular therapies for type 1 diabetes.Cytokine related therapies for autoimmune diseaseThe novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetesInduction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes.Resveratrol improves salivary dysfunction in a non-obese diabetic (NOD) mouse model of Sjögren's syndrome.Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursorsPancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft.TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine.The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies.Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.Stem cells in the spleen: therapeutic potential for Sjogren's syndrome, type I diabetes, and other disorders.Distinctions between islet neogenesis and β-cell replication: implications for reversal of Type 1 and 2 diabetes.TNF, TNF Inducers and TNFR2 Agonists: A New Path to Type 1 Diabetes Treatment.Beta cell dysfunction and insulin resistance
P2860
Q21134119-DAAAD4CF-5948-4C98-8399-764DDBB85EE4Q24674948-101E1853-BD4D-46DA-83B2-5A593BB260EFQ33286067-EF24D9E9-B3C6-4556-92D7-476D1105E8A6Q33525549-71589E44-5FC6-48D9-9F33-99142AC44C9BQ33566004-EC20BFE3-1D43-4271-8EEF-838A1D888429Q33647542-447D58F9-B8BA-4EEF-A474-46C7963938E6Q33759539-F2070940-86C5-4288-8117-99BCBDF97369Q34251616-5F3F3869-1EA8-466B-979B-9ECF47CCABD8Q34299698-24F57589-4F57-4603-B769-38D4CC726535Q34520643-9D944BD7-2AA4-4499-9C7A-43A046B30CB3Q34615453-D8996641-AD4A-47D6-ADED-6BC13C5CA9FEQ34703152-EA7CDBA8-0559-4B09-9E9E-D788718BB9A2Q34703796-A021D927-6078-44CD-9B2E-BD66F5D2BF77Q34770205-FCB40AEF-7B09-412F-9E1D-ECE62F06CE6AQ35094665-402EF368-AFD7-42B4-8B8D-8AF7A8344090Q35165534-D2F9DA75-2C46-42F0-8901-5005CFC84751Q35613139-5E07FA1F-BBC2-4320-9488-A81B39B8FEF0Q35754074-3670EB40-A2FE-4ADB-A12E-7613BB949169Q35942076-08BA3639-50BE-4E8E-9987-824ECD222C2FQ36116497-539E6776-0FAC-4427-B7EF-39E3FE26D073Q36167431-E29DC587-0C3E-4FD5-BE23-BB93C4051AF0Q36225473-7D46F14C-2AE3-461F-8D1B-E865A283E711Q36263810-6A14E135-A4D9-4121-BC4F-E52EE43BE2F3Q36321376-58978DD5-7D1B-48A3-B2BB-8F7CCDFDD69BQ36925952-860A0B0A-C12C-4C60-9D2F-0E52EAFB193EQ36950884-5A609634-8729-4473-8371-389FB58EBE41Q37003015-52C09BC7-0A0A-43AD-A18A-973ECF9F7FD4Q37105570-477D43D6-CF3C-4164-9AAC-99086B30489AQ37160327-2E97866D-D5A5-4E9B-87B6-27F9B76CAA15Q37185883-DE269590-B540-4C5D-8031-64064DEC834DQ37247050-A480BCBA-3929-4083-9E20-3E6E4461A5B3Q37369142-9AFDB01E-9797-4DFB-8A37-7C0B0F34879AQ37372782-8AB7BFF2-380F-4F66-87CA-94E15D42E492Q37408682-7879E67F-F5A9-49E7-A35A-4DF18FDDAD67Q37582803-16C33A42-D44C-4209-82A8-3F965806D274Q37704840-03EB3C61-3D78-4406-80E5-35720AD61572Q37769927-6EBBEDBE-A78F-47AF-BC0C-6199DC600C85Q37798048-2D8C525E-8138-471D-B58D-34D3B2EA1B6FQ38607412-2C3500FB-B4E6-49C1-8DC0-E248D6C6DE5BQ39325879-2A4D8B4F-7DE4-45DA-9B67-34B633ED81F3
P2860
Reversal of established autoimmune diabetes by restoration of endogenous beta cell function
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Reversal of established autoim ...... endogenous beta cell function
@ast
Reversal of established autoim ...... endogenous beta cell function
@en
Reversal of established autoim ...... endogenous beta cell function
@nl
type
label
Reversal of established autoim ...... endogenous beta cell function
@ast
Reversal of established autoim ...... endogenous beta cell function
@en
Reversal of established autoim ...... endogenous beta cell function
@nl
prefLabel
Reversal of established autoim ...... endogenous beta cell function
@ast
Reversal of established autoim ...... endogenous beta cell function
@en
Reversal of established autoim ...... endogenous beta cell function
@nl
P2093
P2860
P3181
P356
P1476
Reversal of established autoim ...... endogenous beta cell function
@en
P2093
P2860
P3181
P356
10.1172/JCI12335
P407
P577
2001-07-01T00:00:00Z